Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial

Increased D-dimer concentrations are associated with poor cardiovascular and other clinical outcomes in people with treated HIV infection. Proteinase activated receptor-1 (PAR-1) is activated by thrombin and overexpressed by immune cells from HIV-infected people. We aimed to study the efficacy of vo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet HIV 2018-10, Vol.5 (10), p.e553-e559
Hauptverfasser:	Kent, Stephen J, Hough, Sally, Kelleher, Anthony D, Law, Matthew G, Hutchinson, Jolie, Catalfamo, Marta, van Bockel, David, Lane, Cliff, Baker, Jason V, Emery, Sean
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents - therapeutic use Biomarkers - blood Double-Blind Method Female Fibrin Fibrinogen Degradation Products - metabolism Hemorrhage - chemically induced HIV Infections - blood HIV Infections - complications HIV Infections - drug therapy HIV Infections - immunology Humans Inflammation - etiology Inflammation - prevention & control Lactones - adverse effects Lactones - therapeutic use Male Middle Aged Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Pyridines - adverse effects Pyridines - therapeutic use Receptor, PAR-1 - antagonists & inhibitors T-Lymphocytes - drug effects Thrombophilia - etiology Thrombophilia - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!